The successful candidate will advise on a broad range of regulatory matters, including regulatory submissions, interactions with health authorities, product approvals, product labeling, pharmacovigilance obligations, post-marketing commitments, and evolving global regulatory requirements. Our revolutionary treatments for conditions like achondroplasia (the most common form of dwarfism), PKU (phenylketonuria), CLN2, a form of Batten disease, and a number of forms of MPS (mucopolysaccharidosis) offer new possibilities for patients and families who previously had few, if any, available options.